// App-Quantinova.ai

1368 : The impact of bevacizumab on combination low-dose afatinib and cetuximab therapy in lung cancer cells harboring activated EGFR mutations

Researchers

Presenter

  • Kenichiro Kudo

Principal Investigators

  • Kadoaki Ohashi

  • Eiki Ichihara

  • Katsuyuki Kiura

  • Daisuke Minami

  • Hisao Kubo

  • Akiko Sato

  • Yuka Kato

  • Hideko Isozaki

  • Hiroe Kayatani

  • Tomoki Tamura

  • Mitsune Tanimoto

Medical Centers

  • Okayama University Hospital Respiratory Medicine, Okayama, Japan

Locations

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Venous thrombosis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Plasminogen activator ihnibitor-1

  • Epidermal growth factor receptor

  • Vascular endothelial growth factor A

Drug/Treatment

  • Bevacizumab

  • Erbitux

  • Afatinib

  • Tiplasinin

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved